New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy

doi:10.16139/j.1007-9610.2021.06.006

Abstract

CLC Number:

R736.1

HUANG Naisi, CHEN Jiaying, Jl Qinghai, QANG Yu. New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 493-496.

Figures/Tables 1

References 20

[1]	田文, 樊友本, 房居高, 等. 局部晚期甲状腺癌手术治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(4):369-376.
[2]	Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer[J]. Surgery, 2016, 160(3):738-746.
[3]	Chen W, Sun K, Zheng H, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12.
[4]	Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases[J]. J Clin Endocrinol Metab, 1999, 84(11):4043-4049.
[5]	Beasley NJ, Walfish PG, Witterick I, et al. Cause of death in patients with well-differentiated thyroid carcinoma[J]. Laryngoscope, 2001, 111(6):989-991.
[6]	Hartl DM, Zago S, Leboulleux S, et al. Resection margins and prognosis in locally invasive thyroid cancer[J]. Head Neck, 2014, 36(7):1034-1038.
[7]	Rubens RD, Sexton S, Tong D, et al. Combined chemotherapy and radiotherapy for locally advanced breast cancer[J]. Eur J Cancer, 1980, 16(3):351-356.
[8]	Tsuboi M, Takizawa H, Aoyama M, et al. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report[J]. Int J Surg Case Rep, 2017, 41:89-92.
[9]	Iwasaki H, Toda S, Ito H, et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy[J]. Case Rep Endocrinol, 2020, 2020:6438352.
[10]	Stewart KE, Strachan MWJ, Srinivasan D, et al. Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report[J]. Eur Thyroid J, 2019, 8(2):102-107.
[11]	Danilovic DLS, Castro G Jr, Roitberg FSR, et al. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer[J]. Arch Endocrinol Metab, 2018, 62(3):370-375.
[12]	Nava CF, Scheffel RS, Cristo AP, et al. Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2019, 10:712.
[13]	Cleary JM, Sadow PM, Randolph GW, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib[J]. J Clin Oncol, 2010, 28(23):e390-e392.
[14]	Golingan H, Hunis B, Golding AC, et al. Neoadjuvant Lenvatinib in advanced unresectable medullary thyroid carcinoma: a case report[J]. AACE Clin Case Rep, 2019, 6(2):e73-e78.
[15]	Jozaghi Y, Zafereo M, Williams MD, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer[J]. Head Neck, 2021, 43(1):E7-E12.
[16]	Cabanillas ME, Ferrarotto R, Garden AS, et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma[J]. Thyroid, 2018, 28(7):945-951.
[17]	Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF^V600E-mutated anaplastic thyroid carcinoma[J]. Thyroid, 2019, 29(8):1036-1043.
[18]	Huang NS, Wei WJ, Xiang J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: a single-arm phase Ⅱclinical trial[J]. Thyroid, 2021[online ahead of print].
[19]	Li D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial[J]. Clin Cancer Res, 2021, 27(13):3567-3575.
[20]	Chi Y, Gao M, Zhang Y, et al. LBA 88 anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phaseⅡ trial[J]. Ann Oncol, 2020, 31(S4):S1215.

病理类型	基因状态	药物选择	常用药物
分化型甲状腺癌		多靶点酪氨酸激酶抑制剂	索拉非尼、仑伐替尼等
髓样癌	RET野生型	多靶点酪氨酸激酶抑制剂	安罗替尼、凡他尼布、卡博替尼等
	RET突变型	RET特异性抑制剂	塞尔帕替尼、普拉替尼
未分化癌	BRAF野生型	多靶点酪氨酸激酶抑制剂+/-PD1	法米替尼、阿帕替尼等
	BRAF突变型	BRAF抑制剂+MEK抑制剂+/-PD1	达拉非尼+曲美替尼

New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 20

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HE Wen, GU Jianhua, XING Xujian, WENG Ziyi, FEI Jian. Tracheal diverticula discovered during surgery: a report of 2 cases and literature review [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 383-387.
[2]	KONG Weiqi, HE Jun, YANG Chengguang, LIU Weiwei, XU Yingjie. Pheochromocytoma with papillary thyroid carcinoma: one case report [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 162-165.
[3]	YAN Haibo, XIA Zhongping, CHEN Shan, JIANG Lin, HAN Chun. Risk factors for Delphian lymph node metastasis in papillary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 453-457.
[4]	LI Rui, LIU Zhuoran, YAN Jiqi. Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 271-275.
[5]	CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben. Diagnosis and treatment of medullary thyroid carcinoma-an update [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 276-280.
[6]	WU Chunxiao, GU Kai, PANG Yi, BAO Pingping, WANG Chunfang, SHI Liang, XIANG Yongmei, GONG Yangming, DOU Jianming, WU Mengyin, FU Chen, SHI Yan. Thyroid cancer incidence and mortality in Shanghai China 2016 and trends from 2002 to 2016 [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 58-65.
[7]	LIU Rongyao, LI Xiangcui, WANG Lina, CHEN Haizhen. Analysis of risk factors for cervical lymph node metastasis in papillary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 76-79.
[8]	WANG Xudong. Interpretation of more aggressive papillary thyroid microcarcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 486-492.
[9]	Ll Changlin, SUN Hui. Brief introduction to technology development of nerve monitoring during thyroid surgery in China [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 482-485.
[10]	WANG Tiantian, Xie Qiuping, WANG Ping. Robotic lateral neck lymph node dissections for thyroid surgery [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 476-481.
[11]	YAO Jing, LI Chen, TIAN Wen. Standardization in diagnosis and treatment of thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 467-471.
[12]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 564-567.
[13]	FAN Jinfang, SHEN Yi, ZHAN Weiwei, TAO Lingling, LI Weiwei, KUANG Lijun, ZHOU Wei. Clinicopathological analysis of papillary thyroid microcarcinoma in isthmus [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 528-531.
[14]	ZHANG Gang, ZHANG Zhe, ZHANG Shu, LI Zhirong, TIAN Wuguo, HUANG Qi, WANG Lingli, XU Yan. Association between RET genotype and disease phenotype in patients with hereditary medullary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 522-527.
[15]	SUN Hanxing, SHEN Xiaohui, GAO Haoji, LIU Zhuoran, CHEN Xi, QIU Weihua, YAN Jiqi. Preoperative evaluation and preparation of Graves′ disease: a report of 126 cases [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 517-521.